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Abstract
Recent studies have shown that a large proportion of patients classified as essential thrombo-
cythemia (ET) actually have early primary prefibrotic myelofibrosis (prePMF), which implies an
inferior prognosis as compared to patients being diagnosed with so-called genuine or true ET.
According to theWorld Health Organization (WHO) 2008 classification, bonemarrow histology
is a major component in the distinction between these disease entities. However, the differen-
tial diagnosis between themmay be challenging and several studies have not been able to dis-
tinguish between them. Most lately, it has been argued that simple blood tests, including the
leukocyte count and plasma lactate dehydrogenase (LDH) may be useful tools to separate
genuine ET from prePMF, the latter disease entity more often being featured by anemia, leu-
kocytosis and elevated LDH.Whole blood gene expression profiling was performed in 17 and
9 patients diagnosed with ET and PMF, respectively. Using elevated LDH obtained at the time
of diagnosis as a marker of prePMF, a 7-gene signature was identified which correctly pre-
dicted the prePMF group with a sensitivity of 100% and a specificity of 89%. The 7 genes
includedMPO,CEACAM8,CRISP3,MS4A3,CEACAM6,HEMGN, andMMP8, which are
genes known to be involved in inflammation, cell adhesion, differentiation and proliferation.
Evaluation of bone marrow biopsies and the 7-gene signature showed a concordance rate of
71%, 79%, 62%, and 38%. Our 7-gene signature may be a useful tool to differentiate between
genuine ET and prePMF but needs to be validated in a larger cohort of “ET” patients.
Introduction
The Philadelphia-negative myeloproliferative neoplasms (MPNs) include essential thrombo-
cythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) [1]. Recent studies
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have shown that a large proportion of patients classified as ET actually have early primary pre-
fibrotic myelofibrosis (prePMF) [2–14]. Since prognosis and likely in the future also treatment
of these entities are different, it is important to distinguish between them [8,11]. According to
the WHO 2008 classification, bone marrow histology is a major component in the distinction
between ET and prePMF [2–14]. However, the differential diagnosis between these two entities
may be challenging and some studies have not been able to distinguish between them [15–16].
Most lately, it has been argued that simple blood tests–the hemoglobin (Hb) concentration, the
leukocyte count and plasma lactate dehydrogenase (LDH)—may be useful tools to separate
genuine ET from early prePMF, the latter disease entity more often being featured by anemia,
leukocytosis and elevated LDH [12]. Genome wide expression profiling data has been used to
perform classification in patients with ET, PV and PMF [17–19]. However, to our knowledge,
no study has applied a supervised classification model to distinguish between genuine ET and
early prePMF. Herein, we report that a simple gene signature–composed of a few genes–in our
whole blood gene expression profiling design [20–26] is able to separate true ET from early
prePMF.
Materials and Methods
Seventeen patients with ET were enrolled in the study. All patients were diagnosed according
to the World Health Organization (WHO) 2008 criteria [27] and followed in two institutions
in Denmark. Most patients were on cytoreductive therapy, which for the large majority
included hydroxyurea (HU). The study was performed in accordance with the Helsinki decla-
ration and was approved by the local ethics committee.
Samples were collected in Paxgene tubes (Preanalytix, Hombrechtikon, Switzerland) and
stored at room temperature for 24 hours, then at -20°C for minimum one day, and finally
transferred to a -80°C freezer. The Paxgene Blood RNA kit (Qiagen, Franklin Lakes, NJ, USA)
was applied to isolate total RNA from whole blood. Quantity of RNA was assessed with the
NanoDrop spectrophotometer ND-8000 (NanoDrop Technologies), and RNA integrity was
determined with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). 300 ng of
purified RNA was converted to biotin-labeled amplified RNA (aRNA) using the Message-
AmpTM III RNA amplification kit (Ambion, Austin, TX). Fragmented aRNA was hybridized
to Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix, Santa Clara, CA, USA).
Data preprocessing and statistical analysis of microarrays were done in the R statistical soft-
ware (www.r-project.org). The robust multi-array average expression measure (rma) was used
to perform background correction, normalization, and expression index calculation [28]. Only
perfect match probes were used for data analysis. Data are available from Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession no. GSE26049).
Gene expression values for all microarray chips were uploaded to DNA-chip Analyzer
(dChip) software [29] and filtering of genes with high variation across all samples was per-
formed. To uncover unknown patterns in the filtered data set, an unsupervised method, princi-
pal component analysis (PCA) was applied to the filtered gene list.
Plasma lactate dehydrogenase (LDH) and the leukocyte count at the time of diagnosis were
used to divide patients into subgroups with different risks for a specific outcome. Because mea-
surement of plasma LDH in all patients was done using different references, the LDH value
required dichotomization into either normal range (genuine ET) or elevated range (prePMF),
taking into account the assumption that the large majority of patients with genuine ET have
normal or only slightly elevated LDH, whereas patients with prePMF exhibit elevated LDH val-
ues. Likewise, patients with leukocyte counts below or above 10.0 x 109/L were assigned to the
group of patients with genuine ET or prePMF, respectively. The patients in the genuine ET or
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prePMF groups are defined as having either low or high risk of developing post-ET myelofibro-
sis or overt PMF, respectively.
Microarray data were used to develop a supervised classification model to predict the out-
come of ET patients. Whole blood from patients with ET and PMF and from healthy controls
were used for gene expression profiling. Only 1 of 9 patients with PMF received treatment.
Comparing gene expression in PMF patients vs. controls, the 12 genesMPO, CEACAM8,
ELA2, DEFA4, OLFM4, CRISP3,MS4A3, CEACAM6, CTSG, AZU1,HEMGN, andMMP8 are
among the top 20 most significantly upregulated genes. None of these 12 genes is significantly
deregulated in ET vs. controls. The remaining 8 top 20 genes are significantly deregulated in
ET vs. controls and are therefore not considered relevant for classification [19–25]. Genes
deregulated in ET may not be predictive of fibrosis which is one of the diagnostic criteria for
prePMF and PMF. Therefore, to separate patients with prePMF from patients with genuine
ET, these 8 genes are not included in the gene signature.” In our previous paper [25], a distinct
5-gene signature consisting of AZU1, CTSG, ELA2, OLFM4, and DEFA4 identified patients
with advanced MPN; however, in the present paper, we sought to identify a gene signature able
to distinguish prePMF (PMF in early stage) from genuine ET. Therefore, to find a gene signa-
ture with classification performance in prePMF, these 5 genes were omitted from the 12-gene
signature resulting in a 7-gene signature includingMPO, CEACAM8, CRISP3,MS4A3, CEA-
CAM6, HEMGN, andMMP8. Thus, the genes in the 7-gene signature are chosen based on
gene expression results from patients with PMF vs. controls.
The performance of the 7-gene signature as a classifier in the ET patients was tested using
support vector machine (SVM) and leave one out cross validation (LOOCV). Using LOOCV
one sample is left out at a time and the rest of the samples is used for classification. Thus, the
sample which is left out and classified is not involved in the training process. Gene expression
values for the 17 ET patients for the selected 7 genes were uploaded to the SVM classification
procedure in the statistical program R using the package e1071 to build a hyperplane to sepa-
rate the genes in the data set with maximal margin. Classification and cross validation leaving
one sample out at a time (LOOCV) were performed, a probability for prePMF was calculated,
and the classification accuracy determined. The model strategy is outlined in Fig 1.
We also tried to perform supervised classification with SVM and LOOCV using the top 500
significant genes obtained from the t-test (genuine ET patients vs. prePMF patients) using both
the leukocyte and LDH values obtained at the time of diagnosis to separate the genuine ET
patients from the prePMF patients. The performance of the models was assessed from the
accuracy values which were quite low, and the models may not be suitable for predicting devel-
opment of prePMF (data not shown).
Bone marrow biopsies from the time of diagnosis from all 17 patients were evaluated by 4
hematopathologists with extensive experience in the field of MPN classification. Three bone
marrow biopsies were not suitable for analysis and therefore excluded from the study. Further-
more, two of the 4 hematopathologists classified one of the ET bone marrow biopsies as unsuit-
able. Biopsies were fixed in formalin and embedded in paraffin. The sections were stained with
hematoxylin and eosin and Gordon and Sweet for reticulin. The biopsies were evaluated strictly
according to the WHO-defined morphological criteria [27]. The hematopathologists did not
have access to any cytological material and was blinded to all clinical data except patient age.
Five diagnoses were used for the histological evaluation: ET, PV, prePMF, overtPMF and
“other”.
Literature research and gene ontology analysis were performed to describe the biological
function of the 7 genes, and biological network analysis was done using the Igenuity1 Pathway
AnalysisTM Software (IPA, www.ingenuity.com). The IPA software includes the Ingenuity
Knowledge Base (IKB) and the Global Molecular Network (GMN) [30]. IKB is a large curated
7-Gene Signature in Early Pre-PMF
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database with a repository of known biological interactions and functional annotations created
from peer-reviewed publications of individual studies of genes in human, mouse and rat. The
GMN is a large network composed of thousands of genes and gene products that interact with
each other. The global network algorithm uses the information from GMN and the user
uploaded list of genes to create the optimal networks.
Ethics statement
The study was approved by The Regional Scientific Ethical Committees for Southern Denmark
and was performed in accordance with the Helsinki Declaration. All patients provided written
informed consent to participate in the study.
Results
The clinical parameters for all patients are summarized in Table 1.
Based on LDH values obtained at the time of diagnosis, 9 patients were assigned to the gen-
uine ET group and 8 patients were assigned to the prePMF group. According to the LDH
value, no difference in age or the JAK2V617F % between genuine ET and prePMF was
observed. When patients were divided into groups according to the leukocyte value obtained at
the time of diagnosis, 9 patients were assigned to the genuine ET group and 8 patients to the
Fig 1. Outline of the classification procedure using SVM and LOOCV. The classification model is built on the 7
genes. The optimal model was selected and classification accuracy determined.
doi:10.1371/journal.pone.0161570.g001
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prePMF group; however, the composition of the patients in the LDH (Table 1) and leukocyte
groups differed (S1 Table)
Of the 54,675 probe sets on the microarray, 1976 genes met the filtering criteria in dChip.
Unsupervised PCA applied to the filtered gene list revealed a tendency for the prePMF patients
to group together and the genuine ET patients to be more scattered (S1A and S1B Fig). These
results suggest that the PCA may not be optimal to separate the two groups of patients.
To explore the performance of a supervised classification model using a predefined gene set,
we selected the 7 genes that were among the top 20 most significantly upregulated genes in
PMF and not significantly upregulated in ET and not included in the 5-gene signature [25].
The resulting genes includedMPO, CEACAM8, CRISP3,MS4A3, CEACAM6,HEMGN, and
MMP8 (S2 Table). In the classification model, the cut off limit for prePMF was set to 0.47 (8/
17) which is the number of prePMF patients according to the LDH or leukocyte count divided
by the total number of patients.
Using LDH as the biochemical variable, the resulting 7-gene signature correctly predicted 8
of 8 patients in the prePMF group (sensitivity 100%) and correctly classified 8 of 9 patients in
the genuine ET group (specificity 89%) and showed a balanced accuracy of 94% (Fig 2).
A receiver operating characteristics (ROC) curve with confidence intervals is depicted in S2
Fig. The area under the ROC curve (AUC) is 0.958 showing an excellent separation of genuine
ET and prePMF. Using the leukocyte value as the biochemical variable, the 7-gene signature
resulted in 62% sensitivity and 78% specificity and showed a balanced accuracy of 70% (data
not shown).
The performance of the 7-gene signature using LDH at the time of diagnosis as the bio-
chemical variable was tested against the bone marrow evaluation from the hematopathologists.
The concordance between the classification and the 4 hematopathologists was 71%, 79%, 62%,
and 38% (Table 2).
Functional analysis and literature research showed that the 7 genes are involved in key pro-
cesses associated with the pathophysiology of MPNs (Table 3).
CRISP3,MMP8 andMPO are neutrophil granule proteins playing important roles in
immune and inflammatory responses [20, 31–34]. CEACAM6 and CEACAM8 are involved in
cell adhesion, cellular invasiveness, angiogenesis, and inflammation [20, 35–39].MS4A3 is a
hematopoietic cell cycle regulator [40], andHEMGN plays an important role in hematopoietic
development and neoplasms and is also involved in differentiation and proliferation [41–42].
Table 1. Patient characteristics.
Number Age Gender JAK2V617F V617 Therapy LDH
(range) (m/f) (+/-) (%)
Genuine ET 9 62 2/7 5/4 22.1 BU = 1 Normal
(49–85) (0.3–67) ANA = 3
HU = 4
IFN = 1
PrePMF 8 65.3 5/3 4/4 21 HU = 6 Elevated
(35–85) (0.1–58) ANA = 2
Patients are divided into the genuine ET or prePMF group according to the LDH value.
BU = busulphan; ANA = anagrelide; HU = hydroxyurea; IFN = interferon-alpha. LDH = lactate dehydrogenase. Age and V617F are mean and range at the
time of blood sampling for gene expression proﬁling studies. No signiﬁcant difference in age and V617F % was observed. LDH values at the time of
diagnosis.
doi:10.1371/journal.pone.0161570.t001
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To identify interactions of the 7 genes with each other and other genes, molecular network
analysis was performed using IPA software. The resulting network consists of 34 genes both
directly and indirectly connected to the 7 genes (Fig 3).
The top functions of the genes in the resulting network were inflammatory response, cellu-
lar movement, and immune cell trafficking well known to be highly relevant in MPNs [20–25].
Furthermore, NFKB and IL2, which act as hubs—i.e. interacting nodes (genes) with high net-
work degrees assumed to correspond to essential gene products in the cell—in the network, are
known to play central roles in inflammation and immune regulation [43–45].
Fig 2. Classification performance of the 7-gene signature in 17 ET patients using LOOCV and SVM. The y-
axis shows the probability of developing preMF. The x-axis shows the sample number. Red circles to the left of the
vertical line represent patients in the prePMF group and blue circles to the right represent patients in the genuine
ET group. Red circles above the horizontal line to the left are correctly predicted patients with prePMF and blue
circles below the line to the right are correctly classified as genuine ET patients. Circles below the line to the left and
above the line to the right are misclassified patients. Patients are divided according to the LDH value at the time of
diagnosis. Balanced accuracy = 94%.
doi:10.1371/journal.pone.0161570.g002
Table 2. Concordance between classification and bonemarrow evaluation.
Classiﬁcation
(LDH)
Bone marrow evaluation
Pathologist 1 Pathologist 2 Pathologist 3 Pathologist 4
ET PV prePMF ET PV prePMF ET PV prePMF ET PV prePMF
ET 6 0 1 6 0 1 3 0 3 1 2 3
preMF 3 0 4 2 0 5 0 2 5 1 2 4
The concordance between the classiﬁcation and hematopathologist 1, 2, 3, and 4 was 71%, 79%, 62%, and 38%. Three bone marrow biopsies were not
suitable for analysis and therefore excluded from the study. Furthermore, pathologist 3 and 4 classiﬁed one of the ET bone marrow biopsies as unsuitable. In
total, 14 bone marrow biopsies were evaluated by pathologist 1 and 2, and 13 bone marrow biopsies were evaluated by pathologist 3 and 4.
doi:10.1371/journal.pone.0161570.t002
7-Gene Signature in Early Pre-PMF
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Discussion
Primary myelofibrosis is aligned along a biological continuum from the early neoplastic stage
—prefibrotic myelofibrosis–to the advanced metastatic myelofibrosis stage–“myelofibrosis
Table 3. Annotation of the 7 genes.
Gene Symbol Gene Title Functional annotation
MPO myeloperoxidase defense response, oxidative stress, inﬂammation
CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 immune response, cell adhesion
CRISP3 cysteine-rich secretory protein 3 immune response, inﬂammation
MS4A3 membrane-spanning 4-domains, subfamily A, member 3 cell cycle regulator
HEMGN hemogen cell differentiation and proliferation
MMP8 matrix metallopeptidase 8 (neutrophil collagenase) inﬂammation, cell differentiation and proliferation
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 cell-cell signaling, inﬂammation, angiogenesis
doi:10.1371/journal.pone.0161570.t003
Fig 3. The figure illustrates the network from IPA software analysis. The 7 genes are shown in red. The
top functions of the network are inflammatory response, cellular movement and immune cell trafficking. Genes
are represented as nodes and the relationship between genes are represented as edges. Solid lines with an
arrow: acts on molecule; dashed lines: indirect interaction; solid line: direct interaction.
doi:10.1371/journal.pone.0161570.g003
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with myeloid metaplasia” (MMM) [46], which is characterized by bone marrow failure with
severe anemia and huge splenomegaly due to extramedullary hematopoiesis with seeding of
CD34+ positive cells in the spleen, liver and elsewhere [1,47–48]. The egress of CD34+ cells
from the stem cell niches into the circulation has been compared to the metastatic process in
solid tumors [49], in which a large number of chemokines, cytokines and proteolytic enzymes
are deeply involved [23–26, 50–53]. In this process–as well as in the progression of myelofibro-
sis from early cancer stage to the advanced cancer stage (MMM)–inflammation and immune
deregulation is today considered of major importance [21–23, 53–57]. Thus, the MPNs have
been described as “A Human Inflammation Model for Cancer Development” [55], in which
chronic inflammation is considered to be the driving force for clonal evolution, increasing
genomic instability and additional mutations with ensuing leukemic transformation [53–56].
In recent years, several studies and reviews have supported the concept of chronic inflamma-
tion as a highly important factor for disease progression in MPNs as evidenced by a marked
increase in several inflammatory cytokines [53]. Furthermore, whole blood transcriptional pro-
filing studies have shown a massive deregulation of inflammation and immune genes and oxi-
dative stress /antioxidative stress genes as well [21–23,26].
The concept “Early Prefibrotic Myelofibrosis” has since 2008 been included in the WHO-
classification of MPNs [27]. However, several studies have shown that this disease entity may
be difficult to diagnose due to lack of consistency and reproducibility of classical bone marrow
features in ET, PV and PMF [6,16] for reasons discussed elsewhere [13]. Thus, bone marrow
histology has been criticized for insufficiency in discriminating between the 2 entities and
inter-observer variability has been a concern [6]. Regarding genuine ET this entity is histopath-
ologically featured by no or only slight increase in age-matched cellularity, no significant
increase in granulo- and erythropoiesis, prominent large to giant mature megakaryocytes with
hyperlobulated or deeply folded nuclei, dispersed or loosely clustered in the marrow space and
no or very rarely minor increase in reticulin fibers [8]. On the contrary, early prePMF stage is
among others characterized by a marked increase in age-matched cellularity with a pro-
nounced proliferation of granulopoiesis and a reduction of erythroid precursors, prominent
large to giant atypical megakaryocytes with hyperchromatic nuclei often arranged in dense
clusters, and no or no significant increase in reticulin fibers [8]. Clinically, patients with genu-
ine ET have–in general–no enlargement of the spleen, whereas patients with prePMF more
often have an enlarged spleen [8,9,11,12]. Importantly, enlargement of the spleen in genuine
ET and prePMF reflects extramedullary hematopoiesis due to egress of CD34+ cells and pro-
genitors from the bone marrow into the circulation to seed preferentially in the spleen and
liver. This process is intimately associated with an altered proteolytic micromilieau consequent
to in vivo activation of granulocytes and release of their neutrophil granule contents, including
e.g. elastase and other proteolytic enzymes [50,51]. This “metastatic “process may not only be
driven by clonal activation of neutrophil granule release, elicited by e.g. the JAK2V617F-muta-
tion per se [51] but also likely mediated by an inflamed bone marrow milieau [53–56]. Thus,
today chronic inflammation is considered to be the driving force behind clonal evolution in
MPNs [53–57]. Of note, we have previously shown that patients with PMF exhibit a distinct
5-gene signature composed of several genes of importance for neutrophil granule release (e.g.
elastase, defensins) [25]. Furthermore, we have also shown that patients with MPNs are charac-
terized by upregulation of a large number of inflammation and oxidative stress genes [22–
23,26] supporting the contention that chronic inflammation may have a major role in MPN
pathogenesis [53–57], including the process by which CD34+ cells migrate from the bone mar-
row to seed in the spleen and liver [22–23,25–26].
When considering some of the previous studies on genuine ET versus early prePMF, it
remains a concern that several patients with genuine ET actually had an enlarged spleen and
7-Gene Signature in Early Pre-PMF
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leukocytosis as well [8–9,11]. If strictly adhering to the histopathological description of genuine
ET versus early prePMF, patients with genuine ET have no significant granulopoiesis in the
bone marrow8 and accordingly should have no or no significant leukocytosis and no significant
splenomegaly, when taking into account that splenic enlargement implies extramedullary
hematopoiesis due to egress of CD34+ cells and progenitors from the bone marrow consequent
to enhanced granulopoiesis with in vivo activation of granulocytes and ensuing release of neu-
trophil granule contents [50–51]. Regardless, a proportion of genuine ET patients in these
studies had leukocytosis, significant increase in circulating CD34+ cells and enlarged spleens
(the latter accounting for about 15–20%) [8–9,11] but still major findings included significant
differences for leukocyte count, platelet count, serum LDH, circulating CD34 cell count, inci-
dence of palpable splenomegaly, and frequency of grade 1 BM fibrosis–all variables being
greater in early/prePMF than ET [9].
Our present study adds highly important novel information to the above findings. Firstly, it
has unraveled a unique gene signature composed of 7 genes (MPO, CEACAM8, CRISP3,
MS4A3, CEACAM6, HEMGN, andMMP8), which are capable of distinguishing genuine ET
from prePMF with a high sensitivity (100%), specificity (89%) and balanced accuracy (94%)
when using LDH at the time of diagnosis as the biochemical variable. By contrast, using the
leukocyte value at the time of diagnosis as the biochemical variable, the 7-gene signature
resulted in a much lower sensitivity (62%), specificity (78%) and balanced accuracy (70%).
Secondly, when testing the performance of the 7-gene signature using LDH at the time of
diagnosis as the biochemical variable against the bone marrow evaluation from the hemato-
pathologists, the concordance between the classification and the hematopathologists was 71%,
79%, 62%, and 38%. Thirdly, the 7 genes are involved in key processes associated with the
pathophysiology of MPNs, including inflammation and immune deregulation. Thus, CRISP3,
MMP8 andMPO are neutrophil granule proteins that play very important roles in immune
and inflammatory responses [20,31–34]; CEACAM6 and CEACAM8 are involved in cell adhe-
sion, cellular invasiveness, angiogenesis, and inflammation [20,35–39] andMS4A3 is a hemato-
poietic cell cycle regulator [40]. The HEMGN gene plays an important role in hematopoietic
development and neoplasms and is also involved in differentiation and proliferation [41–42].
Fourthly, molecular network analysis disclosed 34 genes which both directly and indirectly
were connected to the 7 genes. Highly interestingly, the top functions of the genes were inflam-
matory response, cellular movement, and immune cell trafficking–all considered of utmost
importance in the pathogenesis and pathophysiology of MPNs [20–26]. To this end, NFKB
and IL2 –in the network acting as hubs i.e. interacting nodes with high network degrees
assumed to correspond to essential gene products in the cell, are known to play central roles in
inflammation and immune regulation [43–45].
Fifthly, plasma LDH was found to associate much better to our 7-gene signature than the
leukocyte count, reflecting plasma LDH to be a more robust biochemical marker of incipient
early myelofibrotic transformation than the leukocyte count. The design of our study does not
allow us to explore this interesting observation in depth. However, it is intriguing to speculate
if elevated plasma LDH levels in prePMF might be indicative of a more enhanced myeloproli-
feration and turnover of malignant cells than in patients with genuine ET. This interpretation
is supported by the inferior survival of early prePMF patients as compared to those patients
with genuine ET [9]. It should be noted that a recent study on the value of LDH in distinguish-
ing PMF from the other MPNs displayed serum LDH to be of limited clinical utility [58].
Although serum LDH levels were higher in patients with PMF, levels were also increased in the
majority of patients with ET and PV with significant overlap between the subgroups. Serum
LDH correlated positively with higher leukocyte and platelet counts, and disease duration in
PMF, suggesting LDH to be a biomarker for disease bulk and/or cellular proliferation. It was
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concluded that LDH lacks specificity for PMF–an observation consistent with the concept of a
biological and phenotypic continuum between ET, PV and PMF [22,23,46,58]. In this perspec-
tive, our findings of LDH being a better marker than the leukocyte count to associate with our
7-gene signature of inflammation, immune deregulation, proliferation, angiogenesis and cell
adhesion in the discrimination between the two entities are only supportive. Thus, elevated
LDHmay also indicate defective erythropoiesis with concurrent intramedullary and extrame-
dullary hemolysis which are prone to occur in PMF-patients [59–67], in particular in the early
myelofibrosis stage, where immune deregulation seems to be more prevalent [59,61–62,66].
Furthermore, the earliest stage in this biological continuum–genuine ET—also includes “triple-
negative” ET patients with no JAK2V617F, CALR orMPLmutations and an exceedingly
favourable prognosis, suggesting that these patients may have a less severe form of ET or, alter-
natively, that some of these “ET” patients may actually not have any overt MPN but rather
thrombocytosis associated with a more benign process [68–69]. By contrast, patients with early
prePMF are already along the road towards “myelofibrosis with myeloid metaplasia” as
assessed by more patients with anemia, leukocytosis, elevated LDH and palpable spleens [8–
9,11–12,46].
Our study has limitations and strengths. Firstly, it should be taken into account that our
patients were not newly diagnosed but investigated at different time points after diagnosis.
However, both LDH and leukocyte count were obtained at the time of diagnosis. Secondly,
many patients were treated with HU at the time of microarray analysis, which potentially
might have impacted the ‘‘global gene signature”. However, in our previous whole blood gene
expression studies of MPN-patients on HU treatment, several genes were significantly and
increasingly deregulated from the early MPN stage (ET/PV) to the advanced myelofibrosis
stage, indicating that HU treatment does not seem to have a major impact upon the different
genes being investigated (e.g. inflammation and immune genes) [22–23,26]. Moreover, the
7-gene signature is developed on genes highly significantly deregulated in patients with PMF
vs. control subjects with only 1 of 9 PMF patients receiving treatment. Thirdly, we used whole
blood instead of e.g. isolated granulocytes, CD34+ cells and mononuclear cells, which have
been used in many previous transcriptional profiling studies in MPNs. In the context of explor-
ing distinct genes of value in the discrimination of genuine ET versus prePMF, we believe that
such a discriminatory gene expression profile may be more reliably obtained from transcrip-
tional profiling of whole blood than if isolated cell types were analysed. Indeed, our previous
studies of whole blood transcriptional profiling are strongly supportive, since these studies–in
addition to confirming gene signatures obtained by analyzing single cells by others but gener-
ally with much stronger signals–also have unravelled deregulation of several genes which may
be involved in disease pathogenesis and progression [20,21–26]. As being underscored else-
where [26], our approach certainly also makes sense when considering that the ‘‘tumor tissue”
being studied–whole blood–is composed of clonal ‘‘tumor” cells (being both myeloid cells,
platelets, B-cells and T-cells) and non-clonal cells, including immune cells, which are all acti-
vated due to e.g. chronic inflammation and oxidative stress which are considered of crucial
importance in MPN-disease pathogenesis [53–57]. In this regard, whole blood transcriptional
profiling is actually very similar to all other studies of gene signatures in tumor tissue. Accord-
ingly, in the context of studying powerful gene signatures in the discrimination between genu-
ine ET and early prePMF, our approach with whole blood transcriptional profiling is more a
strength than a limitation. Fourthly, our study included a limited number of ET patients. How-
ever, the fact that we were able to isolate a 7-gene signature using sophisticated and highly
informative gene methodologies in such a small cohort of patients is supportive of our gene sig-
nature possessing a high discriminatory power. However, this observation needs to be
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demonstrated and validated in larger cohorts of ET-patients using our whole blood gene
expression profiling design.
In conclusion, we have for the first time shown that a simple 7-gene signature—composed
of genes involved in inflammation, immune regulation, cell proliferation, angiogenesis and cell
adhesion—is able to discriminate between genuine ET and early prePMF. Considering the con-
cern in regard to reproducibility of histopathological findings to discriminate between these
disease entities [6], further studies are urgently needed which by other methodologies aim at
identifying and distinctly separating these subsets of MPN-patients. In this regard, a recent
study by Pahl et al is of particular importance, showing quantitative NF-E2 immunohistochem-
istry of bone marrow biopsies of MPN patients with thrombocytosis to be of value in distin-
guishing ET from early prePMF [70]. Studies are in progress to validate our results in larger
cohorts of “ET” patients with concomitant NF-E2 immunohistochemistry on bone marrow
biopsies. Hopefully, this combinatorial approach using whole blood gene expression profiling
together with bone marrow NF-E2 immunohistochemistry may yield novel important infor-
mation to be included in decision making on treatment and prognosis of patients with ET and
prePMF.
Supporting Information
S1 Fig. Principal component analysis on the 17 ET patients. The analysis was performed on
the 1976 genes with highest variation across all samples. Blue circles: genuin ET; red circles:
pre-MF. (A) Patients are divided according to the LDH value. (B) Patients are divided accord-
ing to the leukocyte value.
(TIF)
S2 Fig. Receiver operator characteristics (ROC) curve. The ROC curve shows the perfor-
mance of the 7-gene signature. The area under the ROC curve (AUC) is 0.958 showing an
excellent separation of genuine ET and prePMF.”
(TIF)
S1 Table. Patients are divided into the genuine ET or pre-PMF group according to the leu-
kocyte value. BU = busulphan; ANA = anagrelide; HU = hydroxyurea; IFN = interferon-alpha.
Age and V617F are mean and range at the time of blood sampling for gene expression profiling
studies. No significant difference in age and V617F % was observed. Leukocyte values at the
time of diagnosis.
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